Genmab launches new case against Janssen, demands compensation and royalties

Despite recently losing a court case against US-based Janssen concerning milestone payments for cancer drug Darzalex Faspro, the Danish firm is now initiating new arbitration.

Photo: Genmab/PR

Danish biotech firm Genmab has commenced new arbitration against its US-based partner Janssen.

Genmab is seeking USD 405m plus interest on accrued milestone payments for Darzalex Faspro, as well as a new 13-year royalties contract backdated to the first commercial sale of the drug.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs